• Dicot Pharma flagged three LIB-01 abstracts selected for oral presentation at the SMSNA meeting in Orlando on Oct. 8-11, 2026.
• Results have not yet been presented; the data are scheduled for the Innovation Session on Oct. 9.
• Clinical updates point to durable improvements in erectile function from an oral, first-in-class therapy concept with a long duration of action.
• The company also outlined a Phase 2b study design built around LIB-01’s prolonged pharmacodynamic profile, following positive Phase 2a topline results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dicot Pharma AB published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.